- Home
- HSHP vs GLUE Comparison
HSHP vs GLUE Comparison
Compare HSHP & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- GLUE
- Stock Information
- Founded
- HSHP 2021
- GLUE 2019
- Country
- HSHP Bermuda
- GLUE United States
- Employees
- HSHP N/A
- GLUE N/A
- Industry
- HSHP
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- GLUE Health Care
- Exchange
- HSHP Nasdaq
- GLUE Nasdaq
- Market Cap
- HSHP 268.6M
- GLUE 308.8M
- IPO Year
- HSHP 2023
- GLUE 2021
- Fundamental
- Price
- HSHP $8.14
- GLUE $10.05
- Analyst Decision
- HSHP
- GLUE Buy
- Analyst Count
- HSHP 0
- GLUE 2
- Target Price
- HSHP N/A
- GLUE $13.50
- AVG Volume (30 Days)
- HSHP 151.6K
- GLUE 1.2M
- Earning Date
- HSHP 11-20-2025
- GLUE 11-06-2025
- Dividend Yield
- HSHP 5.54%
- GLUE N/A
- EPS Growth
- HSHP N/A
- GLUE N/A
- EPS
- HSHP 0.14
- GLUE 0.29
- Revenue
- HSHP $120,680,000.00
- GLUE $177,986,000.00
- Revenue This Year
- HSHP $9.48
- GLUE $77.63
- Revenue Next Year
- HSHP $31.39
- GLUE N/A
- P/E Ratio
- HSHP $59.18
- GLUE $34.16
- Revenue Growth
- HSHP 44.77
- GLUE 2990.57
- 52 Week Low
- HSHP $4.29
- GLUE $3.50
- 52 Week High
- HSHP $8.95
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- HSHP 50.09
- GLUE 68.94
- Support Level
- HSHP $7.81
- GLUE $7.24
- Resistance Level
- HSHP $8.23
- GLUE $11.47
- Average True Range (ATR)
- HSHP 0.18
- GLUE 0.65
- MACD
- HSHP -0.04
- GLUE 0.20
- Stochastic Oscillator
- HSHP 56.94
- GLUE 66.42
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.